Upstream Bio Inc UPB

$5.04 0.00 (—)

Valuation

Market cap
276,046,000
Revenue TTM
$2,850,000
Net income TTM
$-143,440,000
PE ratio
0.00
Forward PE
—
Profit margin
-5,032.98%
Debt to equity
0.00

Trading

Volume
956,500
Avg volume
624,900
Day's range
$4.86 – $5.21
Shares out
54,771,000
Stochastic %K
26%
Beta
1.38
Analysts
Strong Sell
Price target
$33.67

Price

Company profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was inco...

Show more

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 208 2466
Website
https://upstreambio.com
Address
890 Winter Street, Suite 200, Waltham, United States

Latest news